Screen 20shot 202017 08 07 20at 209.15.12 20pm

Third Eye Diagnostics, Inc.

Novel medical device to non-invasively measure intracranial pressure, critical in assessing the extent of traumatic brain injury and management of hydrocephalus

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Jenkintown, PA, US
  • Currency USD
  • Founded October 2010
  • Employees 5
  • Incorporation Type C-corp
  • Website

Company Summary

3ED has developed a breakthrough medical device to non-invasively measure intracranial pressure (ICP), which is critical in evaluating the onset & extent of traumatic brain injury and in the management of hydrocephalus. 

• Funded & technically validated by National Science Foundation
• Prototype ready for clinical trial at UPenn, Dept. Neurocritical Care 
• High margin/volume recurring revenue 
• $21B TAM 
• 4 patents and 1 pending applications


  • Default avatar
    Terry A Fuller
    President and CEO

    Terry A. Fuller, Ph.D. has over 25 years of entrepreneurial business management, technology development, marketing and sales experience with emerging and high-growth start-up and early-stage medical device and pharmaceutical companies. He has held positions of CEO, COO, and EVP Technology for both publicly traded and private corporations (IOLab, a J&J Co., Surgical Laser Technologies, Inc., Wellcore, Inc., Laser SkinToner, Inc., SubLase, Inc.)

  • Default avatar
    Anthony J Bellezza

    Anthony Bellezza, Ph.D. has direct experience in the formation and operation of startup companies. Prior to Third Eye Diagnostics, he was a Senior Engineer in the Biomechanics Practice at Exponent, Inc., and assisted companies ranging from startups to Fortune 500 in new product development. Scientifically, he has spent much of his career studying the mechanical properties of the eye, especially in response to changes in intraocular pressure.

  • Default avatar
    William Lai
    VP of Biomedical Engineering

    William Lai, Ph.D. has experience with a variety of diagnostic medical devices from intellectual property, regulatory compliance, and product development perspectives. Dr. Lai has conducted research in the biocompatibility of biomaterials used in dental and orthopedic applications at the University of Pennsylvania. He has 5 years experience in the research and development operations of an early stage medical technology development company.


  • Default avatar
    Baker & Hostetler, LLP

Previous Investors

  • Default avatar
    Ben Franklin Technology Partners Northeast
    Default avatar
    National Science Foundation
    Default avatar
    Angel Investor